MitoRx Therapeutics Appoints Neil Anderson as Chief Business Officer
Neil joins from Novo Nordisk and brings more than 20 years of experience in business development and strategic transactionsAppointment strengthens MitoRx’s business development capabilities as the Company advances MTRX31 towards the clinic for metabolically unhealthy obesity Harwell Oxford, UK – 3 November 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, today announces the appointment of Neil Anderson, Ph
Neil joins from Novo Nordisk and brings more than 20 years of experience in business development and strategic transactionsAppointment strengthens MitoRx’s business development capabilities as the Company advances MTRX31 towards the clinic for metabolically unhealthy obesity Harwell Oxford, UK – 3 November 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, today announces the appointment of Neil Anderson, Ph
What's Your Reaction?
